Stelvio Therapeutics
Stelvio Oncology is dedicated to personalizing cancer treatments through innovative epigenetic marker-based diagnostics and therapeutics. Their focus is on developing personalized approaches to glioblastoma treatment, targeting drug resistance mechanisms, and advancing precision medicine. The company emphasizes scientific creativity, clinical excellence, and professional management to successfully bring novel drug therapies and diagnostics to market.
Industries
Nr. of Employees
small (1-50)
Stelvio Therapeutics
https://stelvio-oncology.a-zcompanies.com/contact
Products
Epigenetic signature based platform
A platform for identifying compounds that drive differentiation of cancer stem cells into benign cell types.
Precision Medicine for Glioblastoma
A personalized approach to treating glioblastoma, focusing on overcoming drug resistance and loss of response.
Identifying resistance mechanisms
Techniques for identifying resistance mechanisms in cancer to develop targeted therapies.
Epigenetic signature based platform
A platform for identifying compounds that drive differentiation of cancer stem cells into benign cell types.
Precision Medicine for Glioblastoma
A personalized approach to treating glioblastoma, focusing on overcoming drug resistance and loss of response.
Identifying resistance mechanisms
Techniques for identifying resistance mechanisms in cancer to develop targeted therapies.
Services
Development of predictive diagnostic assays and patient stratification methods based on image-derived epigenetic signatures for oncology applications.
Screening service using epigenetic-signature-based assays to identify compounds that alter cancer stem cell fate and promote differentiation as a therapeutic strategy.
Development of predictive diagnostic assays and patient stratification methods based on image-derived epigenetic signatures for oncology applications.
Screening service using epigenetic-signature-based assays to identify compounds that alter cancer stem cell fate and promote differentiation as a therapeutic strategy.
Expertise Areas
- Precision medicine for glioblastoma
- Epigenetic biomarker-based diagnostics
- Cancer stem cell–targeted therapeutics
- Phenotypic drug screening and discovery
Key Technologies
- Image-based epigenetic marker analysis
- Epigenetic signature profiling
- Phenotypic screening for differentiation
- Predictive diagnostic assay development
News & Updates
September 26, 2017 marked the day Stelvio joined Johnson & Johnson Innovation JLABS in San Diego, California. This vibrant ecosystem is a catalyst for innovation with a capital efficient no strings attached business model. This enables Stelvio to focus on its mission to deliver innovative medicines of value to patients and being a resident of JLABS provides exposure to key deal makers for R&D collaborations.
Alexey Terskikh, PhD, Chief Scientific Officer of Stelvio will be presenting in the track titled "Epigenetic Enzymes in Drug discovery" and in the session "Epigenetic Modification & Transcriptional Regulation."
Stelvio Oncology was featured in Indie Bio's Demo Day, showcasing their innovative cancer therapeutics technology.
A conversation highlighting how Stelvio is discovering novel cancer therapeutics with their innovative technology.
Stelvio was featured as an emerging company in BioCentury, highlighting their work in personalized medicine for glioblastoma.
September 26, 2017 marked the day Stelvio joined Johnson & Johnson Innovation JLABS in San Diego, California. This vibrant ecosystem is a catalyst for innovation with a capital efficient no strings attached business model. This enables Stelvio to focus on its mission to deliver innovative medicines of value to patients and being a resident of JLABS provides exposure to key deal makers for R&D collaborations.
Alexey Terskikh, PhD, Chief Scientific Officer of Stelvio will be presenting in the track titled "Epigenetic Enzymes in Drug discovery" and in the session "Epigenetic Modification & Transcriptional Regulation."
Stelvio Oncology was featured in Indie Bio's Demo Day, showcasing their innovative cancer therapeutics technology.
A conversation highlighting how Stelvio is discovering novel cancer therapeutics with their innovative technology.
Stelvio was featured as an emerging company in BioCentury, highlighting their work in personalized medicine for glioblastoma.